Investigational drugs for the treatment of osteoarthritis (Q38597565)

4 September 2017

title

Investigational drugs for the treatment of osteoarthritis (English)

1 reference

4 September 2017

1 reference

David J Hunter

1 reference

4 September 2017

Kang Wang

1 reference

4 September 2017

Jianhua Xu

series ordinal

1 reference

4 September 2017

Changhai Ding

series ordinal

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 October 2015

1 reference

Expert Opinion on Investigational Drugs

4 September 2017

published in

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

page(s)

1539-1556

1 reference

Osteoarthritis: an update with relevance for clinical practice

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

International variation in hip replacement rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Update on research and future directions of the OMERACT MRI inflammatory arthritis group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Drug utilization in patients with OA: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

COX-2 inhibition: what we learned--a controversial update on safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Articular cartilage and changes in arthritis: matrix degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Increased serum ADAMTS-4 in knee osteoarthritis: a potential indicator for the diagnosis of osteoarthritis in early stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Drug insight: aggrecanases as therapeutic targets for osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Targeting of ADAMTS5's ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

The amelioration of cartilage degeneration by ADAMTS-5 inhibitor delivered in a hyaluronic acid hydrogel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

The long-term prognosis for severe damage to weight-bearing cartilage in the knee: a 14-year clinical and radiographic follow-up in 28 young athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Mono‐iodoacetate‐induced experimental osteoarthritis. A dose‐response study of loss of mobility, morphology, and biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Fibroblast growth factor control of cartilage homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Intra-articular injection of rhFGF-18 improves the healing in microfracture treated chondral defects in an ovine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Basic fibroblast growth factor stimulates matrix metalloproteinase-13 via the molecular cross-talk between the mitogen-activated protein kinases and protein kinase Cdelta pathways in human adult articular chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Fibroblast growth factor 2: good or bad guy in the joint?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Overview of bone morphogenetic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Should subchondral bone turnover be targeted when treating osteoarthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Soluble macrophage biomarkers indicate inflammatory phenotypes in patients with knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Cross-sectional and longitudinal associations between systemic, subchondral bone mineral density and knee cartilage thickness in older adults with or without radiographic osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Subchondral bone as a key target for osteoarthritis treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Efficacy of zoledronic acid in treatment of teoarthritis is dependent on the disease progression stage in rat medial meniscal tear model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Calcitonin delays the progress of early-stage mechanically induced osteoarthritis. In vivo, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Effects of strontium ranelate on spinal osteoarthritis progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthri

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

OARSI guidelines for the non-surgical management of knee osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Metabolic triggered inflammation in osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Does vitamin D improve osteoarthritis of the knee: a randomized controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Anticytokine therapy for osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{alpha} single-chain Fv antibody (ESBA105) designed for local therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Methotrexate for pain relief in knee osteoarthritis: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Statin use and clinical osteoarthritis in the general population: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Safety, tolerability, pharmacokinetics, and effects on human experimental pain of the selective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Results from clinical trials of a selective ionotropic glutamate receptor 5 (iGluR5) antagonist, LY5454694 tosylate, in 2 chronic pain conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Effect of Intra-articular 4-(S)-amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido]-tetrahydro-2H-4-pyranylcarbonyl} piperazino)-5-oxopentyl](trimethyl)ammonium chloride hydrochloride (MEN16132), a kinin B2 receptor an

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Colchicine effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the Osteoarthritis Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Osteoarthritis--a case for personalized health care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

The biomarkers changes in serum and the correlation with quantitative MRI markers by histopathologic evaluation of the cartilage in surgically-induced osteoarthritis rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1091880

10.1517/13543784.2015.1091880

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference